☰

Wahala M. Wahala, Ph.D. - Publications

Affiliations: 
2009 Microbiology & Immunology University of North Carolina, Chapel Hill, Chapel Hill, NC 
Area:
Microbiology Biology, Virology Biology, Immunology
Tree Info Similar researchers PubMed Report error

11 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Gallichotte EN, Widman DG, Yount BL, Wahala WM, Durbin A, Whitehead S, Sariol CA, Crowe JE, de Silva AM, Baric RS. A New Quaternary Structure Epitope on Dengue Virus Serotype 2 Is the Target of Durable Type-Specific Neutralizing Antibodies. Mbio. 6. PMID 26463165 DOI: 10.1128/Mbio.01461-15  0.728
2013 Mani S, Tripathi L, Raut R, Tyagi P, Arora U, Barman T, Sood R, Galav A, Wahala W, de Silva A, Swaminathan S, Khanna N. Pichia pastoris-expressed dengue 2 envelope forms virus-like particles without pre-membrane protein and induces high titer neutralizing antibodies. Plos One. 8: e64595. PMID 23717637 DOI: 10.1371/Journal.Pone.0064595  0.66
2012 Williams KL, Wahala WM, Orozco S, de Silva AM, Harris E. Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo. Virology. 429: 12-20. PMID 22537810 DOI: 10.1016/J.Virol.2012.03.003  0.718
2012 de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, White LJ, Diamond MS, Baric RS, Crowe JE, de Silva AM. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proceedings of the National Academy of Sciences of the United States of America. 109: 7439-44. PMID 22499787 DOI: 10.1073/Pnas.1200566109  0.706
2012 Wahala WM, Huang C, Butrapet S, White LJ, de Silva AM. Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera. Journal of Virology. 86: 4019-23. PMID 22278250 DOI: 10.1128/JVI.06871-11  0.749
2011 Wahala WM, Silva AM. The human antibody response to dengue virus infection. Viruses. 3: 2374-95. PMID 22355444 DOI: 10.3390/v3122374  0.659
2011 Tissera HA, Ooi EE, Gubler DJ, Tan Y, Logendra B, Wahala WM, de Silva AM, Abeysinghe MR, Palihawadana P, Gunasena S, Tam CC, Amarasinghe A, Letson GW, Margolis HS, De Silva AD. New dengue virus type 1 genotype in Colombo, Sri Lanka. Emerging Infectious Diseases. 17: 2053-5. PMID 22099096 DOI: 10.3201/eid1711.101893  0.585
2011 de Alwis R, Beltramello M, Messer WB, Sukupolvi-Petty S, Wahala WM, Kraus A, Olivarez NP, Pham Q, Brien JD, Brian J, Tsai WY, Wang WK, Halstead S, Kliks S, Diamond MS, et al. In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. Plos Neglected Tropical Diseases. 5: e1188. PMID 21713020 DOI: 10.1371/Journal.Pntd.0001188  0.712
2010 Wahala WM, Donaldson EF, de Alwis R, Accavitti-Loper MA, Baric RS, de Silva AM. Natural strain variation and antibody neutralization of dengue serotype 3 viruses. Plos Pathogens. 6: e1000821. PMID 20333252 DOI: 10.1371/Journal.Ppat.1000821  0.717
2009 Wahala WM, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology. 392: 103-13. PMID 19631955 DOI: 10.1016/j.virol.2009.06.037  0.744
2009 Kanakaratne N, Wahala WM, Messer WB, Tissera HA, Shahani A, Abeysinghe N, de-Silva AM, Gunasekera M. Severe dengue epidemics in Sri Lanka, 2003-2006. Emerging Infectious Diseases. 15: 192-9. PMID 19193262 DOI: 10.3201/Eid1502.080926  0.567
Show low-probability matches.